What is Immuron?
Founded in 1994 and headquartered in Australia, Immuron is a publicly listed biopharmaceutical company dedicated to the development and commercialization of innovative therapeutic solutions. Its primary focus lies in creating orally delivered targeted polyclonal antibodies designed to treat inflammatory-mediated and infectious diseases. The company's commercial and clinical-stage pipeline represents a significant advancement in targeted antibody therapies, aiming to provide novel treatment options for a range of challenging medical conditions.
How much funding has Immuron raised?
Immuron has raised a total of $26.1M across 2 funding rounds:
Stock Offering
$6.1M
Other Financing Round
$20M
Stock Issuance/Offering (2017): $6.1M, investors not publicly disclosed
Other Financing Round (2020): $20M, investors not publicly disclosed
What's next for Immuron?
The recent strategic investment signals a pivotal moment for Immuron, likely enabling the company to accelerate its clinical development programs and expand its commercialization efforts. This substantial backing, part of its overall enterprise-level capital infusion, suggests confidence from investors in Immuron's proprietary technology and its potential to address unmet medical needs. Future strategic initiatives may involve further clinical trials, potential partnerships, and market penetration for its lead candidates, positioning Immuron for sustained growth in the competitive biopharmaceutical landscape.
See full Immuron company page
